<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660773</url>
  </required_header>
  <id_info>
    <org_study_id>0106476</org_study_id>
    <nct_id>NCT04660773</nct_id>
  </id_info>
  <brief_title>PHOTOTHERAPY VERSUS PREGABALIN IN TREATMENT OF REFRACTORY UREAMIC PRURITIS</brief_title>
  <official_title>NARROW BAND UVB PHOTOTHERAPY VERSUS PREGABALIN IN TREATMENT OF REFRACTORY PRURITIS IN END STAGE RENAL DISEASE PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomly assigned into 2 groups:&#xD;
&#xD;
        1. Group A: (20 patients) will receive NB UVB phototherapy 3 sessions per week for 2&#xD;
           months.&#xD;
&#xD;
        2. Group B: (20 patients) will receive pregabalin oral therapy (50mg after each dialysis&#xD;
           session) for 2 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5 D-itching scale</measure>
    <time_frame>two month</time_frame>
    <description>assessment of degree, duration, direction, disability and distribution of itching</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Uremic Pruritis</condition>
  <arm_group>
    <arm_group_label>NB UVB phototherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(20 patients) will receive NB UVB phototherapy 3 sessions per week for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pregabalin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NB UVB phototherapy</intervention_name>
    <description>ultraviolet phototherapy sessions</description>
    <arm_group_label>NB UVB phototherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pregabalin</intervention_name>
    <description>oral medication</description>
    <arm_group_label>pregabalin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 20-60 years.&#xD;
&#xD;
          2. End stage renal disease (the last stage(stage 5) of chronic disease which means&#xD;
             kidneys are only functioning at 10 to 15 percent of their normal capacity and dialysis&#xD;
             or kidney transplant is necessary to stay alive).&#xD;
&#xD;
          3. Refractory uremic pruritis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other causes of pruritis (Dermatological or systemic) e.g. atopic, cholestatic liver&#xD;
             disease.&#xD;
&#xD;
          2. Photosensitivity.&#xD;
&#xD;
          3. Contraindication or allergy to pregabalin.&#xD;
&#xD;
          4. Patients on antipruritic drugs e.g. antihistamines, steroids, emollients, opioid&#xD;
             agonists.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>marwa eldeeb</last_name>
    <phone>01200029774</phone>
    <email>marwa.eldeeb16@alexmed.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Alexandria</city>
        <zip>21521</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alexandria university faculty of medicine</last_name>
      <phone>034862506</phone>
      <email>alexmed@edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Alexandria University</investigator_affiliation>
    <investigator_full_name>marwa eldeeb</investigator_full_name>
    <investigator_title>lecturer of dermatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

